Lesinurad联合非布司他治疗痛风石性痛风:III期临床试验
这项12个月III期试验在痛风石性痛风患者中评估lesinurad联合非布司他的疗效与安全性。结果显示,lesinurad 400 mg联合组第6个月达到血清尿酸<5.0 mg/dl的患者比例显著高于非布司他单药组,200 mg组在其余时间点显著更优;联合治疗还缩小目标痛风石总面积,200 mg安全性可接受。
要点
- lesinurad 400 mg联合非布司他显著提高第6个月血清尿酸达标率。
- lesinurad 200 mg和400 mg联合治疗均显著缩小目标痛风石总面积。
- lesinurad 400 mg组血清肌酐可逆性升高的发生率较高。
核心结论
- lesinurad联合非布司他降低血清尿酸优于非布司他单药,并对痛风石有临床相关附加效应,200 mg安全性可接受。
研究设计与样本
- 12个月III期试验,324例痛风石性痛风患者先接受非布司他80 mg/日3周,再随机加用lesinurad 200 mg、400 mg或安慰剂。
主要发现
- 第6个月血清尿酸<5.0 mg/dl达标率:lesinurad 400 mg组76.1%(P<0.0001),200 mg组56.6%(P=0.13),非布司他单药组46.8%。
- 其余时间点lesinurad 200 mg组达标率显著更高。
- 第12个月至少1个目标痛风石完全消退的比例组间无差异。
- 目标痛风石总面积变化:lesinurad 200 mg组50.1%、400 mg组52.9%,非布司他单药组28.3%(P<0.05)。
- 安全性总体与非布司他单药相当,但血清肌酐升高(多可逆)发生率更高,尤其400 mg组。
关键数值与推荐
- 入组血清尿酸≥8.0 mg/dl(已用降尿酸治疗者≥6.0 mg/dl),且至少1个可测量目标痛风石。
- 主要终点为第6个月血清尿酸<5.0 mg/dl的患者比例。
- 关键次要终点为第12个月至少1个目标痛风石完全消退的患者比例。
临床怎么用
- 对非布司他单药治疗仍需额外降尿酸治疗的痛风石性痛风患者,可考虑联用lesinurad 200 mg。
- 联用lesinurad时需监测血清肌酐,尤其高剂量组可逆性升高更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of lesinurad in combination with febuxostat in a 12-month phase III trial in patients with tophaceous gout. METHODS: Patients with serum urate (UA) ≥8.0 mg/dl (≥6.0 mg/dl with urate-lowering therapy) and ≥1 measurable target tophus were given febuxostat 80 mg/day for 3 weeks before randomization to receive lesinurad (200 or 400 mg daily) or placebo in addition to the febuxostat. The primary end point was the proportion of patients achieving a serum UA level of <5.0 mg/dl (month 6). The key secondary end point was the proportion of patients with complete resolution of ≥1 target tophus (month 12). Other end points included the percentage change in total target tophi area. Safety assessments included adverse events and laboratory data. RESULTS: Patients (n = 324) were predominantly male, with a mean age of 54.1 years. Significantly more patients achieved the serum UA target by month 6 with the addition of lesinurad 400 mg (76.1%; P < 0.0001), but not 200 mg (56.6%; P = 0.13), to the febuxostat therapy as compared with febuxostat alone (46.8%). At all other time points, significantly more patients in the lesinurad 200 mg group achieved the serum UA target. The number of patients with complete tophus resolution was not different between groups. Treatment with lesinurad (200 mg and 400 mg) plus febuxostat reduced the total target tophi area as compared with febuxostat alone (50.1% and 52.9% versus 28.3%, respectively; P < 0.05). Safety was generally comparable with that of febuxostat alone, except for higher rates of predominantly reversible elevations in the serum creatinine level, particularly with lesinurad 400 mg. CONCLUSION: Treatment with lesinurad in combination with febuxostat demonstrated superior lowering of serum UA levels as compared with febuxostat alone, with clinically relevant added effects on tophi and an acceptable safety profile with lesinurad 200 mg in patients with tophaceous gout warranting additional therapy.
引用
- Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol. 2017. PMID: 28597604. doi:10.1002/art.40159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。